Stock listing

NASDAQ:ELTX Elicio Therapeutics, Inc. Stock

Home listing (NASDAQ) of Elicio Therapeutics, Inc.

Follow Elicio Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:ELTX

$1.45 USD -0.14 (-8.8%)

Close on Nov 20, 2026

Past year -81.9% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.44 – $1.59 USDNov 20, 2026
Volume
231,624 sharesNov 20, 2026
Market cap
$41.05M USDAt the close on Nov 20, 2026 · price × 28.31M shares outstanding
52-week range
$1.25 – $16.00 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$631,965 USDMedian day 309,000 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Elicio Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ELTX · Home$1.45 USD-0.14 (-8.8%)231,624$1.47$1.59$1.44$1.59Close on Nov 20, 2026
Frankfurt:9HA€1.25 EUR-0.17 (-12.0%)—€1.35€1.35€1.25€1.42Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ELTX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.45-0.14-8.8%$1.47$1.59$1.44231,624
$1.59+0.16+11.2%$1.44$1.59$1.38549,610
$1.43-0.05-3.4%$1.48$1.54$1.37449,195
$1.48-0.02-1.3%$1.48$1.55$1.43209,497
$1.50-0.06-3.8%$1.57$1.60$1.48327,022
$1.56-0.07-4.3%$1.59$1.645$1.55232,784
$1.63+0.02+1.2%$1.61$1.665$1.53357,213
$1.61-0.035-2.1%$1.69$1.77$1.58197,081
$1.645+0.135+8.9%$1.49$1.74$1.48219,011
$1.51+0.11+7.9%$1.40$1.52$1.25756,112
$1.40-0.16-10.3%$1.58$1.66$1.40281,686
$1.56+0.04+2.6%$1.58$1.64$1.48289,096
$1.52-0.07-4.4%$1.71$1.73$1.445516,878
$1.59-0.09-5.4%$1.75$1.80$1.535330,706
$1.68-0.07-4.0%$1.74$1.78$1.655183,462
$1.75-0.10-5.4%$1.82$1.89$1.745135,951
$1.85+0.02+1.1%$1.80$1.89$1.72216,925
$1.83+0.13+7.6%$1.67$1.835$1.655342,266
$1.70-0.20-10.5%$1.91$1.943$1.64422,974
$1.90-0.04-2.1%$1.94$1.98$1.79464,082
$1.94+0.27+16.2%$1.68$1.97$1.67515,800
$1.67+0.10+6.4%$1.57$1.68$1.52269,900
$1.57+0.02+1.3%$1.52$1.62$1.50275,800
$1.55-0.01-0.6%$1.57$1.595$1.44298,100
$1.56-0.22-12.4%$1.81$1.85$1.55333,400
$1.78-0.01-0.6%$1.78$1.86$1.763169,400
$1.79+0.02+1.1%$1.77$1.91$1.75373,300
$1.77-0.11-5.9%$1.88$1.88$1.73232,000
$1.88-0.01-0.5%$1.90$1.91$1.82164,400
$1.89+0.08+4.4%$1.83$1.92$1.785306,200
$1.81-0.04-2.2%$1.85$1.85$1.74267,000
$1.85-0.03-1.6%$1.87$1.92$1.83138,900
$1.88-0.04-2.1%$1.90$1.96$1.86259,100
$1.920.000.0%$1.93$1.96$1.81200,200
$1.920.000.0%$1.95$1.97$1.85175,900
$1.92+0.10+5.5%$1.82$1.96$1.82310,200
$1.82-0.02-1.1%$1.86$1.86$1.78274,000
$1.84-0.01-0.5%$1.85$1.90$1.77452,500
$1.85+0.01+0.5%$1.85$1.90$1.81222,100
$1.84-0.04-2.1%$1.88$1.90$1.82165,400
$1.88+0.01+0.5%$1.88$2.00$1.81339,700
$1.870.000.0%$1.87$1.895$1.84195,400
$1.87-0.04-2.1%$1.92$1.925$1.82402,600
$1.91+0.02+1.1%$1.92$2.02$1.91483,600
$1.89+0.025+1.3%$1.86$2.00$1.86689,700
$1.865+0.095+5.4%$1.79$1.90$1.785340,200
$1.77-0.22-11.1%$1.90$1.90$1.705629,200
$1.99-0.01-0.5%$2.01$2.02$1.915319,000
$2.00-0.05-2.4%$2.06$2.09$1.95391,700
$2.05-0.06-2.8%$2.14$2.20$2.02445,600
$2.11-0.07-3.2%$2.17$2.20$2.07343,100
$2.18-0.17-7.2%$2.37$2.375$2.17457,400
$2.35-0.06-2.5%$2.42$2.46$2.34324,600
$2.41-0.09-3.6%$2.50$2.50$2.36487,900
$2.50-0.05-2.0%$2.55$2.56$2.465272,700
$2.55-0.01-0.4%$2.57$2.61$2.48397,600
$2.56-0.14-5.2%$2.70$2.71$2.55334,300
$2.70-0.14-4.9%$2.84$2.87$2.70412,200
$2.84-0.16-5.3%$3.00$3.00$2.84421,600
$3.00+0.02+0.7%$3.00$3.05$2.97131,200
$2.98-0.03-1.0%$3.00$3.07$2.96181,900
$3.01+0.03+1.0%$3.00$3.095$2.98223,600
$2.98-0.06-2.0%$3.06$3.06$2.94309,000
$3.04-0.035-1.1%$3.11$3.11$3.03279,200
$3.075-0.055-1.8%$3.11$3.135$3.02207,800

Splits

1 split · NASDAQ:ELTX · every price before a split is adjusted for it

DayRatioWhat
1-for-10Consolidation
Ticker
NASDAQ:ELTX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Elicio Therapeutics, Inc. news

Financings

  • Registered direct offering of shares of common stock

    Aug 13, 2026

    Closed: US$15M in the latest tranche · Titan Partners, a division of American Capital Partners +1

    Dealers: Titan Partners, a division of American Capital Partners (lead), B. Riley Securities, Inc.

    Use of proceeds: Support the planned Phase 1 development of ELI-002 7P in metastatic pancreatic cancer and advance the pipeline

    Closed Jul 6, 2026 · Closed Aug 13, 2026

  • Registered direct offering of common stock

    Jul 2, 2026

    Announced: about US$15M · Titan Partners, a division of American Capital Partners +1

    Dealers: Titan Partners, a division of American Capital Partners (lead), B. Riley Securities, Inc.

    Use of proceeds: Fund planned Phase 1 development of ELI-002 7P in metastatic PDAC, the pipeline and platform, working capital and general corporate purposes

    Announced Jul 2, 2026

  • At-the-market programme of shares under at-the-market program

    Nov 13, 2025

    Tranche closed: US$11.1M raised

    Tranche closed Nov 13, 2025

  • Senior secured promissory note with warrants

    Jun 4, 2025

    Closed: US$10M raised · Warrants at US$7.75 for 60 months

    Buyers: GKCC, LLC (existing investor; $10 million senior secured promissory note and warrants to purchase 103,225 shares)

    Use of proceeds: With existing cash, to support operations into Q1 2026, beyond the AMPLIFY-7P Phase 2 interim analysis expected in Q3 2025

    Closed Jun 4, 2025

Read by 6ix AI from the company's releases

Decks

Elicio Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
20 in the last 12 months · 36 in all · newest Nov 5, 2026 · oldest 2025
Decks
15 decks · latest September 2026

Where Elicio Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ELTX · Home listing · This pageNASDAQUnited StatesUSD
LS Exchange:A3CY4JLS ExchangeGermanyEUR
BOATS:ELTXBOATSUnited StatesUSD
Lang & Schwarz:A3CY4JLang & SchwarzGermanyEUR
gettex:9HAgettexGermanyEUR
Dusseldorf:9HADusseldorfGermanyEUR
Frankfurt:9HAFrankfurtGermanyEUR
Munich:9HAMunichGermanyEUR
Tradegate:9HATradegateGermanyEUR

Log in to ask 6ix AI your own questions about Elicio Therapeutics, Inc.